about
A mutation in a functional Sp1 binding site of the telomerase RNA gene (hTERC) promoter in a patient with Paroxysmal Nocturnal HaemoglobinuriaSevere bone marrow failure due to valganciclovir overdose after renal transplantation from cadaveric donors: four consecutive cases.Portal hypertension and myeloproliferative neoplasms: a relationship revealed.Patients treated with therapeutic plasma exchange: a single center experience.Treatment of patients with immune thrombocytopenia admitted to the emergency room.Acute hepatitis B despite a previous high titer of anti-HBs.Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options.Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin's or Non-Hodgkin's Lymphoma?Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode.Congenital Dyserythropoietic Anemia Type 1: Report of One Patient and Analysis of Previously Reported Patients Treated with Interferon AlphaSarcoidosis mimicking lymphoma on positron emission tomography-computed tomography in two patients treated for lymphoma: two case reportsThe Changing Epidemiology of Bloodstream Infections and Resistance in Hematopoietic Stem Cell Transplantation Recipients.Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients.Pulmonary radiological findings in patients with acute myeloid leukemia and their relationship to chemotherapy and prognosis: a single-center retrospective study.The impact of obesity and insulin resistance on iron and red blood cell parameters: a single center, cross-sectional study.Intracranial extramedullary hematopoiesis in patients with thalassemia: a case report and review of the literature.Methods for individualising factor VIII dosing in prophylaxis.Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.A Polymorphism in the IL-5 Gene is Associated with Inhibitor Development in Severe Hemophilia A PatientsPersonalized prophylaxis in people with hemophilia A: challenges and achievements.Minimal Residual Disease (MRD) Detection with Translocations and T-Cell Receptor and Immunoglobulin Gene Rearrangements in Adult Acute Lymphoblastic Leukaemia Patients: A Pilot Study.Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study.Recurrent Monosomies Confirmed by Interphase FISH in Three Chronic Myeloid Leukemia Cases.Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors.Effects of imatinib mesylate on renin-angiotensin system (RAS) activity during the clinical course of chronic myeloid leukaemia.Generics in chronic myeloid leukemia: current arguments for and against and the established evidence.Intrathecal methotrexate-induced acute cerebellar syndrome.JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome.Inhibitor screening for patients with hemophilia in Turkey.Participation in Physical and Sportive Activities among Adult Turkish People with Haemophilia: A Single Centre Experience.The impact of prothrombotic mutations on factor consumption in adult patients with severe hemophilia.Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.Comment and response to: the significance of early warning in chronic myeloid leukemia.Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience.Unilateral sudden hearing loss as the first sign of chronic myeloid leukemia.Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia.Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.Alemtuzumab in Sézary syndrome: efficient but not innocent.
P50
Q24799321-6F13F7D7-BFF3-45C0-9635-86CA76910ED3Q33385095-2BF7036F-0901-4C75-BA50-CDD922F1B961Q33411130-2E6DFB6D-4414-47C7-A841-1BE14DD9C626Q33419064-53D86DEE-8DE0-495E-B136-9CA83ACA7866Q33431840-B702F1A4-A681-409D-8A6A-AC4B2B04045FQ33977138-45AE0406-F462-4E3E-B648-ACBFF40D3CBEQ35678932-1739AFF6-E038-4275-ABFB-AFC369430FC8Q36038881-1B03AD40-5BCB-45AA-875A-959C4E8DD3DBQ36038909-E43BA835-6A93-4675-B0D4-00E7EAA38CAAQ37048461-788C002B-9CED-45E8-ADE2-6240CA3F6543Q37304318-BE8A0AC2-F2D9-4536-B411-E53DD6AB2AA3Q37417446-687444C3-22B0-4F8A-AB99-936779BA0A1EQ37418970-5A645D76-ED23-460D-A5D4-5CD850CC99A3Q37702804-BB321F8E-B68F-4CC7-A7EF-1CD167EEE935Q37718383-4CB17FFB-AA43-4BCD-A321-874E2EDB8724Q37973379-FC0F33F5-3A96-4ED4-9EF7-8C4E21FA3622Q38222572-345098C1-34DE-49B8-BD7C-700E5A665880Q38594364-4E1361D4-0584-42CC-9248-7767396E6F1EQ38914615-8DA5FFC6-740D-4017-A328-1F189DEAEF05Q38997467-44E68C84-A586-4C3F-BB94-7EC51F7BD3CAQ39708213-C59F02EF-C31E-4D80-A5B8-75162359970EQ40555261-BEF4988A-BC67-4DDE-988A-CA21EEA25D5BQ40921739-7811C47A-E794-4F94-BE6D-477DAC4B64ABQ41253617-193964C0-A1C1-4D90-BF6F-CD27C74D2FE5Q43275290-C7631780-37F6-4DD0-8661-2B25BA1B8C40Q44131281-11679E34-3ACD-40C2-ADBA-30E02C48CDC5Q44411750-2ADB9CB3-69D6-40A7-AC20-A93106E9A8FDQ44985081-90C1C1C6-C98D-4D83-9EFB-3A2838FD0735Q45854865-305DF8E2-8E8C-45DB-8EA1-A7BB878DC6D4Q45872069-7A727291-BA9B-44CD-B5A6-F582C195A458Q45878764-DA66F21B-BF90-4258-861F-DFE8F3F3A96BQ47838580-08C23B81-6237-4E38-A1E0-90014D354112Q48299216-1304F696-B133-4936-BEEF-5FC0106EBAE3Q48599157-0A0F0ADE-8C3A-4B3B-A1A7-135C6C1569C6Q48957864-CD05089C-C1D1-4526-A341-CA9F51AC303AQ49334707-CF274432-57A8-4BE9-AD7C-363B9528017BQ50456812-01D9D5BB-C923-4F4A-B794-A3C4EAB9A2FBQ53194938-E2135873-755E-4810-AFC8-BB0108C7997CQ53262532-4DB89280-2CB5-48C2-A683-734850DACA78Q53520839-FF83926B-3E8E-44C2-AA1F-807F71EBFE39
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Muhlis Cem Ar
@ast
Muhlis Cem Ar
@en
Muhlis Cem Ar
@es
Muhlis Cem Ar
@nl
Muhlis Cem Ar
@sl
type
label
Muhlis Cem Ar
@ast
Muhlis Cem Ar
@en
Muhlis Cem Ar
@es
Muhlis Cem Ar
@nl
Muhlis Cem Ar
@sl
prefLabel
Muhlis Cem Ar
@ast
Muhlis Cem Ar
@en
Muhlis Cem Ar
@es
Muhlis Cem Ar
@nl
Muhlis Cem Ar
@sl
P106
P31
P496
0000-0002-0332-9253